The impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infections in 2020: A summary of data reported to the National Healthcare Safety Network

Lindsey M. Weiner-Lastinger MPH\(^1\), Vaishnavi Pattabiraman MSc, MS, MPH\(^1,2\), Rebecca Y. Konnor MPH\(^1,3\), Prachi R. Patel MPH\(^1,3\), Emily Wong MPH\(^1,2\), Sunny Y. Xu MPH\(^1,3\), Brittany Smith MPH\(^1,4\), Jonathan R. Edwards MStat\(^1\) and Margaret A. Dudeck MPH\(^1\)

\(^1\)Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, \(^2\)Leidos, Atlanta, Georgia, \(^3\)CACI, Atlanta, Georgia and \(^4\)Oak Ridge Institute of Science and Education, Oak Ridge, Tennessee

Abstract

Objectives: To determine the impact of the coronavirus disease 2019 (COVID-19) pandemic on healthcare-associated infection (HAI) incidence in US hospitals, national- and state-level standardized infection ratios (SIRs) were calculated for each quarter in 2020 and compared to those from 2019.

Methods: Central-line–associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs), ventilator-associated events (VAEs), select surgical site infections, and *Clostridioides difficile* and methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia laboratory-identified events reported to the National Healthcare Safety Network for 2019 and 2020 by acute-care hospitals were analyzed. SIRs were calculated for each HAI and quarter by dividing the number of reported infections by the number of predicted infections, calculated using 2015 national baseline data. Percentage changes between 2019 and 2020 SIRs were calculated. Supporting analyses, such as an assessment of device utilization in 2020 compared to 2019, were also performed.

Results: Significant increases in the national SIRs for CLABSI, CAUTI, VAE, and MRSA bacteremia were observed in 2020. Changes in the SIR varied by quarter and state. The largest increase was observed for CLABSI, and significant increases in VAE incidence and ventilator utilization were seen across all 4 quarters of 2020.

Conclusions: This report provides a national view of the increases in HAI incidence in 2020. These data highlight the need to return to conventional infection prevention and control practices and build resiliency in these programs to withstand future pandemics.

(Received 12 July 2021; accepted 15 July 2021)

As the coronavirus disease 2019 (COVID-19) pandemic swept through the United States, regions experienced peak cases and hospitalizations at various times in 2020.\(^1\) The pandemic response placed burden on acute-care hospitals (ACHs), which may have altered staffing practices, increased critical care capacity, and modified use of personal protective equipment (PPE).\(^2,3\) In the early stages of the pandemic, little was known about how COVID-19 hospitalizations would affect the incidence of healthcare-associated infections (HAIs). Single-site studies observed early signs of increases in select HAIs during the spring of 2020.\(^4-6\) Others have studied the occurrence of secondary infections in COVID-19 patients.\(^7-9\) Additionally, a report from the National Healthcare Safety Network (NHSN) found significant increases in central-line–associated bloodstream infections (CLABSIs) during the early months of the pandemic.\(^10\)

The NHSN is the nation’s largest HAI surveillance system and is used by nearly all US hospitals to fulfill local, state, or federal HAI reporting requirements. NHSN data are used to measure progress toward prevention goals; this progress is assessed using an observed-to-predicted ratio called the standardized infection ratio (SIR).\(^11\) Nationally, from 2015 to 2019, there have been consistent, significant reductions in the SIRs for CLABSIs, catheter-associated urinary tract infections (CAUTIs), and *Clostridioides difficile* infection (CDI) laboratory-identified (LabID) events.\(^12-14\) Some significant year-to-year decreases have also been observed in methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia LabID events since 2010.\(^12,13,14\) Conversely, there has been minimal change in the occurrence of ventilator-associated events (VAEs).\(^12\) Given the potential for COVID-19 response activities to impact HAI prevention and surveillance, the NHSN team analyzed national
and state SIRs to identify potential changes in HAI incidence between 2019 and 2020.

**Methods**

CLABSI, CAUTI, VAE, select surgical site infections (SSIs), MRSA labID, and CDI labID events that occurred in ACHs between 2019 and 2020 and were reported to the NHSN Patient Safety Component as of April 1, 2021, were included in this report. Standard surveillance definitions and exclusion rules are described elsewhere for each HAI type.16

CLABSI and CAUTI included in this analysis were those in scope for the Centers for Medicare and Medicaid Services (CMS) Hospital-Acquired Conditions Reduction Program (HACRP).17 The HACRP includes infections that occurred in adult and pediatric intensive care units (ICUs), neonatal ICUs (CLABSI only), and adult and pediatric medical, surgical, and medical–surgical wards. VAE data encompass all events classified as ventilator-associated condition (VAC), infection-related ventilator-associated condition (IVAC), and possible ventilator-associated pneumonia (PVAP). VAE surveillance is not included in the CMS HACRP, but events reported voluntarily or due to a state mandate from adult ICUs and adult wards were included. The SSIs included were a subset of those required under the HACRP and classified as deep incisional or organ-space infections following adult inpatient colon or abdominal hysterectomy procedures, detected during the same admission as the procedure or readmission to the same hospital. LabID event surveillance for both organisms is conducted for facility-wide inpatient (FacWideIN) locations and is required for participation in the HACRP. Hospitals that reported no FacWideIN patient days or admissions for a quarter were excluded from the LabID analysis for that quarter.

Temporal comparisons in HAI incidence between 2019 and 2020 were analyzed using national and state SIRs, calculated for each calendar quarter by dividing the number of reported infections by the number of predicted infections, and they were represented by the relative change in magnitude. The number of predicted infections was obtained using regression models created from the 2015 national baseline data with appropriate risk adjustment for the respective HAI. The complete risk adjustment methodology and criteria used for SIR numerators are summarized in the NHSN SIR Guide.11 SIRs below 1 indicate fewer infections observed than predicted, signaling reductions. Likewise, SIRs above 1 indicate more infections were observed than predicted, signaling increases.

The percentage change between pairs of 2019 and 2020 quarterly SIRs was calculated as follows:

\[
\frac{2020\ SIR - 2019\ SIR}{2019\ SIR} \times 100
\]

The 95% confidence intervals around the percentage change were calculated, and a 2-tailed \( P \leq .05 \) calculated by mid-P exact test was considered statistically significant. Percentile distributions of the 2020 SIRs were calculated using data from hospitals with at least 1 predicted HAI.

To reduce potential inclusion bias, SIR analyses were restricted to hospitals with complete surveillance data for both quarters in each pair of quarterly comparisons and for the same locations when applicable (ie, device-associated infections). Given the nature and impact of the pandemic on ACHs, the CMS issued an HAI reporting exception for 2020-Q1–2020-Q2, allowing hospitals to temporarily pause reporting to the NHSN.18 The impact of this exception was assessed for each HAI type by calculating the percentage of hospitals in 2019-Q1–2019-Q2 that also reported HAI data for 2020-Q1–2020-Q2.

The CDC previously identified the states with a high number of hospitalized COVID-19 patients between April 1 and July 14, 2020.1 To determine the impact of COVID-19 on HAI incidence in these states, the percentage change in state-level Q2 and Q3 SIRs were calculated for CLABSI, CAUTI, VAE, and MRSA bacteremia. For reference, supplemental data tables and interactive maps are provided on the NHSN website (https://www.cdc.gov/nhsn/dataset/index.html) that provide a comparison between 2019 and 2020 quarterly SIRs for all states and all applicable HAI types, as well as a comparison of location-stratified national SIRs for DA infections.

Additional supporting analyses were performed to help inform the changes in SIRs, including a review of the length-of-stay (from patient admission to discharge date), time to event (from device insertion to infection date), and device utilization measured by the standardized utilization ratio (SUR). SURs were calculated by dividing the number of reported device days by the number of predicted device days, based on 2015 national baseline data.19 In addition, the inpatient and outpatient quarterly community-onset MRSA bacteremia prevalence rates were reviewed from 2019-Q1 to 2020-Q4.20 The FacWideIN community-onset prevalence rate was calculated per 1,000 admissions, and the outpatient community-onset prevalence rate was calculated per 10,000 encounters in emergency departments and 24-hour observation units. Data were analyzed using SAS version 9.4 software (SAS Institute, Cary, NC).

**Results**

Most ACHs reporting 2019 HAI surveillance data continued to report data throughout 2020 (Table 1). Between 86% and 88% of hospitals that conducted surveillance for CLABSI, CAUTI, MRSA bacteremia, or CDI during 2019-Q1 or 2019-Q2 also reported surveillance data for 2020-Q1 or 2020-Q2. Larger declines in the number of reporting hospitals were seen for VAE (22–25% drop) and SSI (25%–36% drop) surveillance. Reporting levels during the second half of 2020 were close to those of the prepandemic period for most HAI.

**CLABSI**

Despite an initial 12% decrease in the 2020-Q1 CLABSI SIR compared to 2019-Q1, the SIRs in 2020-Q2–2020-Q4 were significantly higher than those in 2019 (Tables 2–5). The largest year-to-year magnitudes of increase (46%–47%) occurred during Q3 and Q4, with the highest CLABSI SIR of 1.01 occurring during 2020-Q3. The increases in the CLABSI SIRs were driven by larger SIR numerators in 2020; for example, in 2020-Q3, there were 4,460 CLABSIs reported, representing a 53% increase compared to the 2,911 events reported from the same hospitals and locations in 2019-Q3. During the same time, the number of predicted CLABSIs increased by 5% (data not shown).

The change in CLABSI SIR varied by state and quarter (Table 6). Arizona’s CLABSI SIR was 149% higher in 2020-Q2 than 2019-Q2, and the SIR for Massachusetts doubled in 2020-Q2. Louisiana and Michigan experienced statistically significant increases of >70% in their Q2 CLABSI SIRs. Although New Jersey and New York reported nonsignificant changes in their CLABSI SIRs in 2020-Q2, both states had a substantial decline (61% and 40%, respectively) in the number of reporting hospitals in 2020-Q2 compared to 2019.13 The number of reporting
hospitals returned to prepandemic levels in 2020-Q3 for both states, and New Jersey’s 2020-Q3 CLABSI SIR (0.86) was 59% higher than the SIR from 2019-Q3 (0.54). Arizona, Georgia, and Florida observed substantial (97%-148%) increases in their 2020-Q3 state SIRs compared to 2019-Q3.

**CAUTI**

The national CAUTI SIR steadily increased from 2020-Q1 to 2020-Q4, ranging from 0.59 in Q1 to 0.82 in Q4 (Tables 2–5). Significant increases in the 2020 CAUTI SIR compared to 2019 were observed in Q3 and Q4, with the Q4 SIR increasing by 19%, from 0.69 in 2019 to 0.82 in 2020. The increase in the Q4 CAUTI SIR was driven by a 36% increase in the number of infections, from 3,142 in 2019-Q4 to 4,258 in 2020-Q4. The number of predicted CAUTI cases increased by 15% during this period. At the state level, significant increases in the Q3 CAUTI SIR were reported by Arizona (69%) and California (24%) (Table 7). Georgia, Massachusetts, Michigan, and New Jersey each observed >20% increase in their state’s CAUTI SIR for 2020-Q3 compared to 2019-Q3, although these increases were not statistically significant.

**VAE**

Between 1,332 and 1,496 hospitals reported VAE data to NHSN for each quarter in 2019 and 2020 (Tables 2–5). The 2020-Q2 and 2020-Q3 national VAE SIRs were 1.31 and 1.29. Preliminary Q4 data indicated an even higher SIR; 10,108 and 7,296 VAEs were reported and predicted respectively, resulting in a 2020-Q4 SIR of 1.39. Significant increases in the national VAE SIRs were observed in all 4 quarters of 2020 compared to 2019, with the largest increase of 45% occurring in Q4. Many states experienced significant increases in their VAE SIRs in 2020-Q2 and 2020-Q3, such as 88% and 91% increases in the Illinois and New York SIRs for Q2, and an 87% increase in the Georgia SIR for Q3 (Table 8). The median hospital-level VAE SIR for 2020-Q2, 2020-Q3, and 2020-Q4 were all above 1.0, with the highest median SIR of 1.30 occurring in Q4.

**All Device-Associated infections**

Overall, the national distributions of time to infection for CLABSI and CAUTI, or length-of-stay for patients with any device-associated infection were significantly different in 2020 compared to 2019 (not shown). The mean time to infection for ICU CLABSI increased from 8 days in 2019 to 10 days in 2020. The median length of stay for an ICU patient with a CAUTI increased from 17 days in 2019 to 20 days in 2020, and for ICU VAEs, it increased from 17 days in 2019 to 19 days in 2020.

Compared to 2019, central-line and urinary catheter usage were significantly higher in 2020-Q2–2020-Q4, and ventilator usage was significantly higher in all 4 quarters of 2020 (not shown). The central-line SUR increased by 7%, from 0.85 in 2019-Q2–2019-Q4 to 0.91 to 2020-Q2–2020-Q4. The urinary catheter SUR increased by 9%, from 0.81 in 2019-Q2–2019-Q4 to 0.88 in 2020-Q2–2020-Q4. The quarterly ventilator SURs were 25%–31% higher in 2020-Q2–2020-Q4, with the Q4 SUR increasing from 0.94 in 2019-Q4 to 1.23 in 2020-Q4.

**MRSA bacteremia LabID**

The national SIRs for MRSA bacteremia were significantly higher in 2020-Q2, 2020-Q3, and 2020-Q4 compared to 2019, with the 2020 SIRs ranging from 0.77 in Q1 to 1.07 in Q4 (Tables 2–5).

During 2020-Q2, there was a 15% (5 million) reduction in national FaciWideN patient days, an 18% (1.4 million) reduction in admissions, and a 34% (10 million) reduction in outpatient encounters (Appendix A1–A2 online). These decreases in denominators led to increases in the 2020-Q2 inpatient and outpatient community-onset MRSA bacteremia prevalence rates compared to 2019-Q2; there was a small increase in the inpatient community-onset prevalence rate (0.53 vs 0.59 events per 1,000 admissions) and a large increase in the outpatient community-onset prevalence rate (3.66 vs 5.47 events per 10,000 encounters).

The national MRSA bacteremia SIR was 0.92 in 2020-Q2, a 12% increase from 2019-Q2. This increase was largely driven by the decline in patient days in 2020-Q2, which contributed to a 10%
| HAI Type                        | No. of Hospitals | 2020 No. | 2020 Q1 | 2019 Q1 | Device Days, Procedures, or Patient Days | % Change in SIR | 95% CI Around SIR | % Change | 0%  | 25%  | 50%  | 75%  | 90%  | 100% |
|--------------------------------|-----------------|----------|---------|---------|------------------------------------------|-----------------|--------------------|----------|-----|------|------|------|------|------|
| CLABSI                         | 3,130           | 2,236    | 3,738.12| 3,725,983|                                          | 0.60            | 0.68               | −11.8d   | (−17.2 to −7.3) | 0.00 | 0.00 | 0.49 | 0.87 | 1.33 | 4.51 |
| CAUTI                         | 3,129           | 2,449    | 4,152.83| 3,562,137|                                          | 0.59            | 0.75               | −21.3d   | (−33.2 to −20.0) | 0.00 | 0.00 | 0.48 | 0.85 | 1.39 | 4.34 |
| VAE                            | 1,402           | 5,642    | 5,239.51| 756,925  |                                          | 1.08            | 0.97               | 11.3d    | (6.5–14.9)      | 0.00 | 0.00 | 0.83 | 1.86 | 2.82 | 5.87 |
| SSI, colon surgery             | 2,518           | 1,437    | 1,802.05| 71,170   |                                          | 0.80            | 0.88               | −9.1d    | (−15.5 to −2.6)  | 0.00 | 0.00 | 0.75 | 1.35 | 2.01 | 4.41 |
| SSI, abdominal hysterectomy    | 2,269           | 336      | 423.36  | 64,158   |                                          | 0.79            | 0.94               | −16.0d   | (−26.6 to −2.2)  | 0.00 | 0.00 | 0.69 | 0.91 | 1.90 | 3.75 |
| Laboratory-identified MRSA    | 3,176           | 1,689    | 2,205.32| 34,345,939|                                          | 0.77            | 0.83               | −7.2d    | (−13.9 to −1.7)  | 0.00 | 0.00 | 0.69 | 1.11 | 1.75 | 6.59 |
| Laboratory-identified CDI      | 3,190           | 9,910    | 19,231.71| 31,915,519|                                          | 0.52            | 0.63               | −17.5d   | (−20.3 to −16.0) | 0.00 | 0.17 | 0.43 | 0.73 | 1.09 | 3.77 |

Note. CI, confidence interval; CLABSI, central-line–associated bloodstream infection; CAUTI, catheter-associated urinary tract infection; VAE, ventilator-associated event; SSI, surgical site infection; MRSA, methicillin-resistant *Staphylococcus aureus*; CDI, *Clostridioides difficile* infection; NHSN, National Healthcare Safety Network; CMS, Centers for Medicare and Medicaid Services; ICU, intensive care unit.

*aThe number of acute-care hospitals that reported complete HAI surveillance data for both quarters in the comparison.

*bDevice days are shown for CLABSI, CAUTI, and VAE. Procedure counts are shown for SSI. Patient days are shown for laboratory-identified events.

*c% change was calculated as follows: \[(2020 SIR − 2019 SIR) ÷ 2019 SIR\] × 100.

*dStatistical significance based on 2-tailed *P* ≤ .05, reflected in the relative % change in magnitude.

*ePercentile distribution of hospital-level SIRs includes only those hospitals that had at least 1 predicted HAI.

*fCLABSI SIRs were calculated using data from adult and pediatric ICUs, neonatal ICUs, and adult and pediatric medical, surgical, and medical-surgical wards.

*gCAUTI SIRs were calculated using data from adult and pediatric ICUs, and adult and pediatric medical, surgical, and medical-surgical wards.

*hVAE SIRs were calculated using data from adult ICUs and wards.

*iSSIs included are those classified as deep incisional or organ-space infections following adult inpatient procedures that were detected during the same admission as the surgical procedure or upon readmission to the same hospital. The NHSN Complex Admission–Readmission model was used for SIR calculations.

+jMRSA bacteremia SIRs were calculated using data from all inpatient locations in the hospital (facility-wide inpatient, or FacWideIN) except inpatient rehabilitation and inpatient psychiatric units certified by the CMS. Reported and predicted HAIs were limited to hospital-onset events that were identified in an inpatient location on the fourth day (or later) after admission to the facility.

+kCDI SIRs were calculated using data from all inpatient locations in the hospital (FacWideIN) except neonatal ICUs, newborn nurseries, and inpatient rehabilitation and inpatient psychiatric units certified by the CMS. Reported and predicted HAIs were limited to hospital-onset incident events that were identified in an inpatient location on the fourth day (or later) after admission to the facility without a prior positive CDI specimen in the previous 56 days.
### Table 3. National Healthcare-Associated Infection (HAI) Standardized Infection Ratios (SIRs) for Acute-Care Hospitals, April–June 2020 (Q2)

| HAI Type                  | No. of Hospitals<sup>a</sup> | No. of HAIs Reported | No. of HAIs Predicted | Device Days, Procedures, or Patient Days<sup>b</sup> | 2020 Q2 | 2019 Q2 | % Change<sup>c</sup> in SIR | 95% CI Around SIR % Change | Percentile Distribution of 2020 Q2 Hospital-Level SIRs<sup>e</sup> |
|---------------------------|------------------------------|----------------------|-----------------------|------------------------------------------------------|--------|--------|--------------------------|---------------------------|---------------------------------------------------------------|
| CLABSI<sup>f</sup>        | 3,057                        | 2,963                | 3,394.90              | 3,358,039                                            | 0.87   | 0.68   | 27.9<sup>d</sup>          | (21.5–35.2)               | 0.00 0.00 0.68 1.19 1.94 6.54                                  |
| CAUTI<sup>g</sup>         | 3,049                        | 2,590                | 3,831.88              | 3,266,836                                            | 0.68   | 0.71   | −4.2                     | (−9.9 to 0.2)             | 0.00 0.00 0.58 0.97 1.60 4.86                                  |
| VAE<sup>h</sup>           | 1,332                        | 7,191                | 5,495.34              | 800,017                                              | 1.31   | 0.98   | 33.7<sup>d</sup>          | (28.5–38.5)               | 0.00 0.00 1.18 2.33 3.59 12.55                                |
| SSI, colon surgery<sup>i</sup> | 2,443                       | 1,272                | 1,462.82              | 55,790                                               | 0.87   | 0.88   | −1.1                     | (−8.1 to 6.4)             | 0.00 0.00 0.78 1.41 2.00 4.90                                  |
| SSI, abdominal hysterectomy<sup>i</sup> | 2,124                       | 276                  | 303.54                | 44,882                                               | 0.91   | 0.99   | −8.1                     | (−20.6 to 6.9)            | 0.00 0.00 0.89 1.53 1.78 2.99                                  |
| Laboratory-identified MRSA bacteremia<sup>j</sup> | 3,106                       | 1,729                | 1,881.91              | 28,488,801                                           | 0.92   | 0.82   | 12.2<sup>d</sup>          | (5.0–20.0)                | 0.00 0.00 0.75 1.24 1.84 6.77                                  |
| Laboratory-identified CDI<sup>k</sup> | 3,113                       | 8,141                | 15,701.11             | 26,107,710                                           | 0.52   | 0.58   | −10.3<sup>d</sup>         | (−13.8 to −8.7)           | 0.00 0.15 0.42 0.74 1.09 6.13                                  |

Note. CI, confidence interval; CLABSI, central-line–associated bloodstream infection; CAUTI, catheter-associated urinary tract infection; VAE, ventilator-associated event; SSI, surgical site infection; MRSA, methicillin-resistant *Staphylococcus aureus*; CDI, *Clostridioides difficile* infection. NHSN, National Healthcare Safety Network; CMS, Centers for Medicare and Medicaid Services; ICU, intensive care unit.

<sup>a</sup>The number of acute-care hospitals that reported complete HAI surveillance data for both quarters in the comparison.

<sup>b</sup>Device days are shown for CLABSI, CAUTI, and VAE. Procedure counts are shown for SSI. Patient days are shown for laboratory-identified events.

<sup>c</sup>% change was calculated as follows: [(2020 SIR − 2019 SIR) ÷ 2019 SIR] × 100.

<sup>d</sup>Statistical significance based on 2-tailed P ≤ .05, reflected in the relative % change in magnitude.

<sup>e</sup>Percentile distribution of hospital-level SIRs includes only those hospitals that had at least 1 predicted HAI.

<sup>f</sup>CLABSI SIRs were calculated using data from adult and pediatric ICUs, neonatal ICUs, and adult and pediatric medical, surgical, and medical–surgical wards.

<sup>g</sup>CAUTI SIRs were calculated using data from adult and pediatric ICUs, and adult and pediatric medical, surgical, and medical–surgical wards.

<sup>h</sup>VAE SIRs were calculated using data from adult ICUs and wards.

<sup>i</sup>SSIs included are those classified as deep incisional or organ-space infections following adult inpatient procedures that were detected during the same admission as the surgical procedure or upon readmission to the same hospital. The NHSN Complex Admission–Readmission model was used for SIR calculations.

<sup>j</sup>MRSA bacteremia SIRs were calculated using data from all inpatient locations in the hospital (FacWideIN) except inpatient rehabilitation and inpatient psychiatric units certified by the CMS. Reported and predicted HAIs were limited to hospital-onset events that were identified in an inpatient location on the fourth day (or later) after admission to the facility.

<sup>k</sup>CDI SIRs were calculated using data from all inpatient locations in the hospital (FacWideIN) except neonatal ICUs, newborn nurseries, and inpatient rehabilitation and inpatient psychiatric units certified by CMS. Reported and predicted HAIs were limited to hospital-onset incident events that were identified in an inpatient location on the fourth day (or later) after admission to the facility without a prior positive CDI specimen in the previous 56 days.
Table 4. National Healthcare-Associated Infection (HAI) Standardized Infection Ratios (SIRs) for Acute-Care Hospitals, July–September 2020 (Q3)

| HAI Type                  | No. of Hospitals<sup>a</sup> | No. of HAIs Reported | No. of HAIs Predicted | Device Days, Procedures, or Patient Days<sup>b</sup> | 2020 | 2019 | % Change<sup>c</sup> in SIR | 95% CI Around SIR | % Change | 0%  | 25%  | 50%  | 75%  | 90%  | 100% |
|---------------------------|-----------------------------|----------------------|-----------------------|-----------------------------------------------------|------|------|-----------------------------|-------------------|----------|-----|------|------|------|------|------|
| CLABSIf                   | 3,451                       | 4,460                | 4,415.75              | 4,388,693                                           | 1.01 | 0.69 | 46.4<sup>d</sup>            | (39.4–53.1)       | 0.00     | 0.41 | 0.81 | 1.46 | 2.31 | 8.40 |
| CAUTIf                    | 3,448                       | 4,034                | 5,025.69              | 4,263,776                                           | 0.80 | 0.71 | 12.7<sup>d</sup>            | (7.9–18.4)        | 0.00     | 0.22 | 0.69 | 1.18 | 1.86 | 7.00 |
| VAEh                      | 1,496                       | 8,521                | 6,604.97              | 954,394                                             | 1.29 | 1.00 | 29.0<sup>d</sup>            | (24.8–33.8)       | 0.00     | 0.00 | 1.13 | 2.17 | 3.31 | 7.87 |
| SSI, colon surgeryi       | 2,769                       | 1,729                | 2,127.12              | 80,372                                              | 0.81 | 0.87 | −6.9<sup>d</sup>            | (−12.6 to −0.3)   | 0.00     | 0.00 | 0.68 | 1.29 | 1.99 | 4.75 |
| SSI, abdominal hysterectomyi | 2,476                   | 486                  | 488.18                | 71,473                                              | 1.00 | 1.05 | −4.8                       | (−16.2 to 6.7)    | 0.00     | 0.00 | 0.84 | 1.39 | 2.05 | 3.94 |
| Laboratory-identified MRSA bacteremia<sup>j</sup> | 3,512                       | 2,482                | 2,539.42              | 38,333,911                                          | 0.98 | 0.80 | 22.5<sup>d</sup>            | (14.6–29.0)       | 0.00     | 0.29 | 0.78 | 1.43 | 2.08 | 7.35 |
| Laboratory-identified CDI<sup>k</sup> | 3,511                       | 10,875               | 21,087.49             | 35,313,701                                          | 0.52 | 0.57 | −8.8<sup>d</sup>            | (−11.4 to −6.8)   | 0.00     | 0.16 | 0.44 | 0.73 | 1.07 | 8.16 |

Note. CI, confidence interval; CLABSI, central-line–associated bloodstream infection; CAUTI, catheter-associated urinary tract infection; VAE, ventilator-associated event; SSI, surgical site infection; MRSA, methicillin-resistant *Staphylococcus aureus*; CDI, *Clostridioides difficile* infection; NHSN, National Healthcare Safety Network; CMS, Centers for Medicare and Medicaid Services; ICU, intensive care unit.

<sup>a</sup>The number of acute-care hospitals that reported complete HAI surveillance data for both quarters in the comparison.

<sup>b</sup>Device days are shown for CLABSI, CAUTI, and VAE. Procedure counts are shown for SSI. Patient days are shown for laboratory-identified events.

<sup>c</sup>% change was calculated as follows: \[\left(\frac{2020 \text{ SIR} - 2019 \text{ SIR}}{2019 \text{ SIR}}\right) \times 100\].

<sup>d</sup>Statistical significance based on 2-tailed *P* ≤ .05, reflected in the relative % change in magnitude.

<sup>e</sup>Percentile distribution of hospital-level SIRs includes only those hospitals that had at least 1 predicted HAI.

<sup>f</sup>CLABSI SIRs were calculated using data from adult and pediatric ICUs, neonatal ICUs, and adult and pediatric medical, surgical, and medical-surgical wards.

<sup>g</sup>CAUTI SIRs were calculated using data from adult and pediatric ICUs, and adult and pediatric medical, surgical, and medical-surgical wards.

<sup>h</sup>VAE SIRs were calculated using data from adult ICUs and wards.

<sup>i</sup>SSIs included are those classified as deep incisional or organ-space infections following adult inpatient procedures that were detected during the same admission as the surgical procedure or upon readmission to the same hospital. NHSN Complex Admission–Readmission model was used for SIR calculations.

<sup>j</sup>MRSA bacteremia SIRs were calculated using data from all inpatient locations in the hospital (facility-wide inpatient, or FacWideIN) except inpatient rehabilitation and inpatient psychiatric units certified by the CMS. Reported and predicted HAIs were limited to hospital-onset events that were identified in an inpatient location on the fourth day (or later) after admission to the facility.

<sup>k</sup>CDI SIRs were calculated using data from all inpatient locations in the hospital (FacWideIN) except neonatal ICUs, newborn nurseries, and inpatient rehabilitation and inpatient psychiatric units certified by CMS. Reported and predicted HAIs were limited to hospital-onset incident events that were identified in an inpatient location on the fourth day (or later) after admission to the facility without a prior positive CDI specimen in the previous 56 days.
Table 5. Preliminary National Healthcare-Associated Infection (HAI) Standardized Infection Ratios (SIRs) for Acute-Care Hospitals, October–December 2020 (Q4)

| HAI Type                      | No. of Hospitals\(^a\) | No. of HAIs Reported | No. of HAIs Predicted | Device Days, Procedures, or Patient Days\(^b\) | 2020 % Change\(^c\) in SIR | 95% CI Around SIR | % Change 0% 25% 50% 75% 90% 100\% |
|------------------------------|-------------------------|----------------------|-----------------------|-----------------------------------------------|-----------------------------|-------------------|-----------------|-----------------|-----------------|-----------------|------------------|
| CLABSI\(^d\)                | 3,259                   | 4,371                | 4,498.95              | 4,476,688                                      | 0.97                        | 0.66              | 47.0 \(^d\)     | (39.5–53.6)     | 0.00            | 0.34            | 0.81             | 1.40            | 2.05            | 6.48             |
| CAUTI\(^d\)                 | 3,256                   | 4,258                | 5,205.82              | 4,424,667                                      | 0.82                        | 0.69              | 18.8 \(^d\)     | (12.9–23.8)     | 0.00            | 0.22            | 0.71             | 1.24            | 1.85            | 7.41             |
| VAE\(^d\)                   | 1,438                   | 10,108               | 7,296.11              | 1,061,907                                      | 1.39                        | 0.96              | 44.8 \(^d\)     | (38.9–48.7)     | 0.00            | 0.00            | 1.30             | 2.51            | 3.78            | 12.20            |
| SSI, colon surgery\(^d\)    | 2,594                   | 1,469                | 1,899.78              | 72,700                                         | 0.77                        | 0.84              | −8.3 \(^d\)     | (−13.6 to −0.6) | 0.00            | 0.00            | 0.66             | 1.15            | 1.79            | 3.79             |
| SSI, abdominal hysterectomy\(^d\) | 2,322                  | 400                  | 464.40                | 69,145                                         | 0.86                        | 0.99              | −13.1 \(^d\)   | (−23.4 to −0.8) | 0.00            | 0.00            | 0.74             | 0.96            | 1.58            | 7.04             |
| Laboratory-identified MRSA bacteremia\(^d\) | 3,296                  | 2,715                | 2,537.64              | 38,700,892                                     | 1.07                        | 0.80              | 33.8 \(^d\)     | (25.6–41.1)     | 0.00            | 0.39            | 0.80             | 1.47            | 2.28            | 7.82             |
| Laboratory-identified CDI\(^d\) | 3,299                  | 10,987               | 21,139.54             | 35,954,158                                     | 0.52                        | 0.55              | −5.5 \(^d\)     | (−8.0 to −3.1) | 0.00            | 0.16            | 0.43             | 0.72            | 1.07            | 9.25             |

Note. CI, confidence interval; CLABSI, central-line–associated bloodstream infection; CAUTI, catheter-associated urinary tract infection; VAE, ventilator-associated event; SSI, surgical site infection; MRSA, methicillin-resistant Staphylococcus aureus; CDI, Clostridioides difficile infection; ICU, intensive care unit; CMS, Centers for Medicare and Medicaid Services; NHSN, National Healthcare Safety Network.

\(^a\)The number of acute-care hospitals that reported complete HAI surveillance data for both quarters in the comparison.

\(^b\)Device days are shown for CLABSI, CAUTI, and VAE. Procedure counts are shown for SSI. Patient days are shown for laboratory-identified events.

\(^c\)% change was calculated as follows: \([\text{2020 SIR} - \text{2019 SIR}] / \text{2019 SIR}] \times 100.\)

\(^d\)Statistical significance based on 2-tailed \( P \leq .05 \), reflected in the relative % change in magnitude.

\(^e\)Percentile distribution of hospital-level SIRs includes only those hospitals that had at least 1 predicted HAI.

\(^f\)CLABSI SIRs were calculated using data from adult and pediatric ICUs, neonatal ICUs, and adult and pediatric medical, surgical, and medical–surgical wards.

\(^g\)CAUTI SIRs were calculated using data from adult and pediatric ICUs, and adult and pediatric medical, surgical, and medical–surgical wards.

\(^h\)VAE SIRs were calculated using data from adult ICUs and wards.

\(^i\)SSI SIRs included are those classified as deep incisional or organ-space infections following adult inpatient procedures that were detected during the same admission as the surgical procedure or upon readmission to the same hospital. The NHSN Complex Admission–Readmission model was used for SIR calculations.

\(^j\)Laboratory-identified events were calculated using data from all inpatient locations in the hospital (FacWideIN) except neonatal ICUs, newborn nurseries, and inpatient rehabilitation and inpatient psychiatric units certified by the CMS. Reported and predicted HAIs were limited to hospital-onset events that were identified in an inpatient location on the fourth day (or later) after admission to the facility.
| State | No. of Hospitals | 2020 Q2 No. of CLABSiS | 2020 Q2 SIR | 2019 Q2 SIR | % Change<sup>d</sup> in SIR | 95% CI Around SIR | 2020 Q3 No. of CLABSiS | 2020 Q3 SIR | 2019 Q3 SIR | % Change<sup>d</sup> in SIR | 95% CI Around SIR |
|-------|------------------|------------------------|-------------|-------------|----------------|--------------------|------------------------|-------------|-------------|----------------|----------------|
| Arizona | 59 | 80 | 82.63 | 0.97 | 0.39 | 148.7<sup>e</sup> | (64.6–275.6) | 59 | 105 | 92.20 | 1.14 | 0.46 | 147.8<sup>e</sup> | (72.5–269.2) |
| California | 300 | 309 | 358.57 | 0.86 | 0.61 | 41.0<sup>e</sup> | (18.5–66.6) | 323 | 536 | 436.18 | 1.23 | 0.70 | 75.7<sup>e</sup> | (51.9–102.8) |
| Florida | 189 | 166 | 241.80 | 0.69 | 0.72 | −4.2 | (−22.0 to 18.1) | 207 | 381 | 312.59 | 1.22 | 0.62 | 96.8<sup>e</sup> | (65.7–137.0) |
| Georgia | 100 | 131 | 155.77 | 0.84 | 0.59 | 42.4<sup>e</sup> | (9.4–86.5) | 103 | 238 | 172.12 | 1.38 | 0.68 | 102.9<sup>e</sup> | (61.7–156.6) |
| Illinois | 111 | 129 | 126.73 | 1.02 | 0.69 | 47.8<sup>e</sup> | (12.4–91.9) | 129 | 111 | 166.12 | 0.67 | 0.68 | −1.5 | (−23.9 to 28.7) |
| Louisiana | 65 | 47 | 39.87 | 1.18 | 0.69 | 71.0<sup>e</sup> | (7.9–174.3) | 85 | 101 | 69.75 | 1.45 | 0.89 | 62.9<sup>e</sup> | (18.4–125.6) |
| Massachusetts | 59 | 109 | 87.77 | 1.24 | 0.62 | 100.0<sup>e</sup> | (45.1–181.7) | 65 | 81 | 95.71 | 0.85 | 0.63 | 34.9 | (−3.9 to 86.7) |
| Michigan | 76 | 119 | 91.17 | 1.31 | 0.75 | 74.7<sup>e</sup> | (29.6–136.3) | 94 | 111 | 130.22 | 0.85 | 0.64 | 32.8<sup>e</sup> | (0.1–77.2) |
| New Jersey | 28 | 37 | 32.93 | 1.12 | 0.81 | 38.3 | (−18.1 to 137.8) | 67 | 76 | 88.38 | 0.86 | 0.54 | 59.3<sup>e</sup> | (10.7–127.9) |
| New York | 100 | 73 | 121.75 | 0.60 | 0.61 | −1.6 | (−29.4 to 34.9) | 168 | 249 | 285.50 | 0.87 | 0.77 | 13.0 | (−5.3 to 35.6) |
| Pennsylvania | 156 | 222 | 215.55 | 1.03 | 0.77 | 33.8<sup>e</sup> | (10.4–64.3) | 155 | 197 | 234.26 | 0.84 | 0.80 | 5.0 | (−13.7 to 29.2) |
| Texas | 302 | 242 | 305.15 | 0.80 | 0.73 | 9.6 | (−8.4 to 31.1) | 322 | 487 | 395.20 | 1.23 | 0.73 | 68.5<sup>e</sup> | (45.8–97.8) |

Note. CI, confidence interval; CDC, Centers for Disease Control and Prevention; NHSN, National Healthcare Safety Network; ICU, intensive care unit.

<sup>a</sup>SIRs were calculated using data from adult and pediatric ICUs, neonatal ICUs, and adult and pediatric medical, surgical, and medical–surgical wards.

<sup>b</sup>Quarterly CLABSI SIRs are available for all eligible states and quarters in the Supplementary Tables (online). The states shown in this table were identified by the CDC as having a high number of hospitalized COVID-19 patients between April 1, 2020, and July 14, 2020.

<sup>c</sup>Hospitals reporting complete CLABSI surveillance data to the NHSN for the same location for both quarters in the comparison.

<sup>d</sup>% change was calculated as follows: [(2020 SIR − 2019 SIR) / 2019 SIR] × 100.

<sup>e</sup>Statistical significance based on 2-tailed $P \leq .05$, reflected in the relative % change in magnitude.
Table 7. 2020 Q2 and Q3 Catheter-Associated Urinary Tract Infection (CAUTI) Standardized Infection Ratios (SIRs) for Acute-Care Hospitals Compared to 2019 for Select States

| State       | 2020 Q2 vs 2019 Q2 | 2020 Q3 vs 2019 Q3 |
|-------------|---------------------|---------------------|
|             | No. of Hospitals    | No. of CAUTIs       | No. of Predicted CAUTIs | 2020 Q2 SIR | 2019 Q2 SIR | % Change in SIR | 95% CI Around SIR | % Change in SIR | 2020 Q3 SIR | 2019 Q3 SIR | % Change in SIR | 95% CI Around SIR |
| Arizona     | 61                   | 50                 | 81.37                    | 0.61 | 0.37 | 64.9*          | (4.9–161.2)      | 61             | 85           | 93.35        | 0.91 | 0.54 | 68.5*          | (15.6–144.5)       |
| California  | 294                  | 339                | 388.79                   | 0.87 | 0.87 | 0.0            | (−13.4 to 16.8)  | 318            | 494          | 470.01       | 1.05 | 0.85 | 23.5*          | (7.8–41.7)         |
| Florida     | 188                  | 123                | 265.60                   | 0.46 | 0.62 | −25.8*         | (−40.7 to −6.3)  | 206            | 224          | 338.48       | 0.66 | 0.59 | 11.9           | (−8.7 to 36.0)     |
| Georgia     | 101                  | 100                | 161.07                   | 0.62 | 0.73 | −15.1          | (−35.4 to 10.9)  | 104            | 167          | 193.47       | 0.86 | 0.68 | 26.5           | (−0.9 to 61.9)     |
| Illinois    | 110                  | 91                 | 140.55                   | 0.65 | 0.70 | −7.1           | (−30.6 to 23.6)  | 130            | 132          | 181.88       | 0.73 | 0.70 | 4.3            | (−18.9 to 33.3)    |
| Louisiana   | 64                   | 44                 | 50.37                    | 0.87 | 0.84 | 3.6            | (−31.7 to 57.7)  | 85             | 58           | 86.92        | 0.67 | 0.80 | −16.3          | (−41.5 to 19.5)    |
| Massachusetts | 59                 | 105                | 101.67                   | 1.03 | 0.99 | 4.0            | (−21.6 to 38.7)  | 65             | 95           | 108.33       | 0.88 | 0.71 | 23.9           | (−9.3 to 67.7)     |
| Michigan    | 76                   | 69                 | 113.94                   | 0.61 | 0.65 | −6.2           | (−32.6 to 30.2)  | 94             | 134          | 162.37       | 0.83 | 0.66 | 25.8           | (−3.6 to 60.5)     |
| New Jersey  | 29                   | 23                 | 41.40                    | 0.56 | 0.99 | −43.4*         | (−67.8 to −4.0)  | 68             | 82           | 99.15        | 0.83 | 0.64 | 29.7           | (−7.8 to 79.9)     |
| New York    | 99                   | 74                 | 150.94                   | 0.49 | 0.78 | −37.2*         | (−53.6 to −16.0) | 167            | 255          | 342.35       | 0.74 | 0.85 | −12.9          | (−26.2 to 3.6)     |
| Pennsylvania | 156                | 211                | 263.25                   | 0.80 | 0.66 | 21.2           | (−0.3 to 49.0)   | 155            | 206          | 273.93       | 0.75 | 0.67 | 11.9           | (−8.3 to 37.5)     |
| Texas       | 299                  | 180                | 298.04                   | 0.60 | 0.59 | 1.7            | (−17.0 to 25.0)  | 323            | 292          | 411.87       | 0.71 | 0.62 | 14.5           | (−4.5 to 36.4)     |

Note. CI, confidence interval; CDC, Centers for Disease Control and Prevention; NHSN, National Healthcare Safety Network; ICU, intensive care unit.

*SIrS were calculated using data from adult and pediatric ICUs, and adult and pediatric medical, surgical, and medical-surgical wards.

1Quarterly CAUTI SIRs were available for all eligible states and quarters in the Supplementary Tables (online). The states shown in this table were identified by the CDC as having a high number of hospitalized COVID-19 patients between April 1, 2020, and July 14, 2020.

1Hospitals reporting complete CAUTI surveillance data to the NHSN for the same location for both quarters in the comparison.

6% change was calculated as follows: \( (2020 \text{ SIR} − 2019 \text{ SIR}) / 2019 \text{ SIR} \times 100 \).

*Statistical significance based on 2-tailed \( P \leq .05 \), reflected in the relative % change in magnitude.
| State  | 2020 Q2 vs 2019 Q2 | 2020 Q3 vs 2019 Q3 | 95% CI Around SIR % Change |
|-------|------------------|------------------|---------------------------|
|       | No. of Hospitals | No. of VAEs | No. of Predicted VAEs | No. of VAEs | No. of Predicted VAEs | SIR | 95% CI | % Change |
| Arizona | 20 | 99 | 68.28 | 1.45 | 1.34 | 8.2 | (−22.3 to 47.9) | 17 | 83 | 90.53 | 0.92 | 0.91 | 1.1 | (−26.2 to 46.3) |
| California | 135 | 664 | 532.01 | 1.25 | 1.07 | 16.8 | (1.6–28.8) | 156 | 878 | 709.83 | 1.24 | 1.04 | 19.2 | (4.2–29.5) |
| Florida | 107 | 531 | 388.45 | 1.37 | 1.14 | 20.2 | (4.2–34.4) | 112 | 956 | 552.00 | 1.73 | 1.07 | 61.7 | (39.4–76.3) |
| Georgia | 52 | 457 | 370.17 | 1.24 | 0.78 | 59.0 | (31.3–80.7) | 50 | 597 | 421.90 | 1.42 | 0.76 | 86.8 | (50.8–107.9) |
| Illinois | 35 | 176 | 121.20 | 1.45 | 0.77 | 88.3 | (38.2–155.9) | 44 | 105 | 118.60 | 0.89 | 0.78 | 14.1 | (−16.8 to 50.1) |
| Louisiana | 22 | 132 | 85.89 | 1.54 | 1.17 | 31.6 | (−2.9 to 68.5) | 26 | 128 | 104.95 | 1.22 | 0.86 | 41.9 | (0.0–83.7) |
| Massachusetts | 15 | 146 | 77.64 | 1.88 | 1.27 | 48.0 | (5.9–87.1) | 19 | 59 | 52.33 | 1.13 | 1.27 | −11.0 | (−36.9 to 28.5) |
| Michigan | 37 | 342 | 207.62 | 1.65 | 1.32 | 25.0 | (1.0–41.2) | 43 | 337 | 236.48 | 1.43 | 1.26 | 13.5 | (−5.4 to 29.7) |
| New Jersey | 21 | 86 | 77.39 | 1.11 | 0.82 | 35.4 | (−14.4 to 109.9) | 43 | 159 | 188.48 | 0.84 | 0.76 | 10.5 | (−12.2 to 39.7) |
| New York | 48 | 159 | 246.50 | 0.65 | 0.34 | 91.2 | (38.8–155.7) | 97 | 341 | 482.43 | 0.71 | 0.64 | 10.9 | (−5.3 to 28.6) |
| Pennsylvania | 115 | 863 | 617.58 | 1.40 | 0.94 | 48.9 | (30.3–63.0) | 111 | 648 | 556.45 | 1.17 | 1.03 | 13.6 | (0.9–27.4) |
| Texas | 101 | 519 | 420.98 | 1.23 | 0.87 | 41.4 | (27.0–68.9) | 103 | 903 | 553.69 | 1.63 | 0.96 | 69.8 | (46.8–89.5) |

Note. CI, confidence interval; CDC, Centers for Disease Control and Prevention; NHSN, National Healthcare Safety Network; ICU, intensive care unit.

aSIRs were calculated using data from adult ICUs and adult wards.
bQuarterly VAE SIRs are available for all eligible states and quarters in the Supplementary Tables [online]. The states shown in this table were identified by the CDC as having a high number of hospitalized COVID-19 patients between April 1, 2020, and July 14, 2020. The states in this table were identified by the CDC as having a high number of hospitalized COVID-19 patients between April 1, 2020, and July 14, 2020.1

cHospitals reporting complete VAE surveillance data to the NHSN for the same location for both quarters in the comparison.
d% change was calculated as follows: (2020 SIR − 2019 SIR) × 100.

eStatistical significance based on 2-tailed P ≤ .05, reflected in the relative % change in magnitude.
### Table 9. 2020 Q2 and Q3 Laboratory-Identified (LabID) Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bacteremia* Standardized Infection Ratios (SIRs) for Acute-Care Hospitals Compared to 2019 for Select States

| State | 2020 Q2 vs 2019 Q2 | 2020 Q3 vs 2019 Q3 |
|-------|---------------------|---------------------|
|       | No. of Hospitals c  | No. of Hospital-onset MRSA Bacteremia d | No. of Predicted Hospital-onset MRSA Bacteremia d | SIR | % Change e in SIR | 95% CI Around SIR | % Change e in SIR | 95% CI Around SIR |
| Arizona | 61 | 46 | 47.57 | 0.97 | 0.54 | 79.6 f | (12.4–189.9) | 63 | 50 | 54.89 | 0.91 | 0.66 | 37.9 | (–12.5 to 122.3) |
| California | 301 | 138 | 168.72 | 0.82 | 0.80 | 2.5 | (–19.0 to 28.7) | 325 | 162 | 204.71 | 0.79 | 0.61 | 29.5 f | (2.8–64.6) |
| Florida | 188 | 168 | 161.09 | 1.04 | 1.04 | 0.0 | (–18.5 to 24.3) | 208 | 260 | 207.15 | 1.26 | 1.11 | 13.5 | (–5.6 to 35.9) |
| Georgia | 98 | 87 | 72.57 | 1.20 | 0.79 | 51.9 f | (10.3–110.9) | 102 | 114 | 92.97 | 1.23 | 1.02 | 20.6 | (–9.6 to 59.8) |
| Illinois | 110 | 69 | 69.68 | 0.99 | 0.68 | 45.6 f | (1.1–111.9) | 128 | 69 | 83.86 | 0.82 | 0.65 | 26.2 | (–10.9 to 82.2) |
| Louisiana | 67 | 31 | 24.02 | 1.29 | 1.34 | –3.7 | (–41.5 to 58.5) | 85 | 82 | 40.54 | 2.02 | 1.03 | 96.1 f | (35.1–187.0) |
| Massachusetts | 60 | 49 | 51.66 | 0.95 | 0.86 | 10.5 | (–25.8 to 66.0) | 66 | 43 | 60.94 | 0.71 | 0.70 | 1.4 | (–34.5 to 56.9) |
| Michigan | 81 | 64 | 50.35 | 1.27 | 0.98 | 29.6 | (–9.6 to 85.2) | 99 | 63 | 79.74 | 0.79 | 0.63 | 25.4 | (–12.7 to 83.3) |
| New Jersey | 31 | 34 | 22.23 | 1.53 | 0.77 | 98.7 f | (13.0–259.1) | 68 | 50 | 61.82 | 0.81 | 0.72 | 12.5 | (–24.8 to 65.5) |
| New York | 91 | 67 | 67.25 | 1.00 | 0.64 | 56.3 f | (7.8–171.1) | 169 | 134 | 170.41 | 0.79 | 0.88 | –10.2 | (–29.4 to 12.1) |
| Pennsylvania | 164 | 96 | 102.89 | 0.93 | 0.62 | 50.0 f | (11.1–104.2) | 164 | 92 | 119.33 | 0.77 | 0.72 | 6.9 | (–19.7 to 44.8) |
| Texas | 307 | 138 | 159.74 | 0.86 | 0.83 | 3.6 | (–17.6 to 30.9) | 330 | 255 | 205.33 | 1.24 | 0.87 | 42.5 f | (18.2–74.5) |

Note. CI, confidence interval; HO, hospital-onset; MRSA, methicillin-resistant *Staphylococcus aureus*; CDC, Centers for Disease Control and Prevention; NHSN, National Healthcare Safety Network; CMS, Centers for Medicare and Medicaid Services.

*aSIRs were calculated using data from all inpatient locations in the hospital (facility-wide inpatient, or FacWideIN) except inpatient rehabilitation and inpatient psychiatric units certified by the CMS.

*bQuarterly MRSA bacteremia SIRs are available for all eligible states and quarters in the Supplementary Data Tables (online). The states shown in this table were identified by the CDC as having a high number of hospitalized COVID-19 patients between April 1, 2020, and July 14, 2020.1

*cHospitals reporting complete MRSA bacteremia LabID event surveillance data to the NHSN for both quarters in the comparison.

*Hospital-onset events are defined as those that were identified in an inpatient location on the fourth day (or later) after admission to the facility.

*% change was calculated as follows: [(2020 SIR – 2019 SIR) / 2019 SIR] × 100.

*fStatistical significance based on 2-tailed *P* ≤ .05, reflected in the relative % change in magnitude.
had been observed across US hospitals.\textsuperscript{12} Except for VAE, the pandemic. HAI incidence, may have been affected by the COVID-19 and provide a national picture of how patient safety, in particular NHSN data are representative of largely all ACHs in the country to 2019 SIRs. Due to reporting requirements for the CMS HACRP, quarterly SIRs for each HAI type in 2020, along with a comparison This report is the first to present national and select state-level

### Discussion

This report is the first to present national and select state-level quarterly SIRs for each HAI type in 2020, along with a comparison to 2019 SIRs. Due to reporting requirements for the CMS HACRP, NHSN data are representative of largely all ACHs in the country and provide a national picture of how patient safety, in particular HAI incidence, may have been affected by the COVID-19 pandemic.

Prior to the pandemic, widespread decrease in HAI incidence had been observed across US hospitals.\textsuperscript{12} Except for VAE, the national 2020-Q1 SIR for each HAI was below 1 and significantly lower than that from 2019-Q1, indicating a continual decline in HAI incidence at the beginning of 2020. As hospitals began to respond to the COVID-19 pandemic in 2020-Q2, increases in national SIRs became apparent. Initial increases in the SIRs were observed early in the year for CLABSI and MRSA bacteremia (starting in 2020-Q2) and for VAE (starting in 2020-Q1). However, compared to 2019, 2020-Q3 and 2020-Q4 saw large and significant increases in the CLABSI, CAUTI, VAE, and MRSA bacteremia SIRs (Fig. 1).

The CLABSI SIR experienced the greatest increase among all HAI types; the heightened CLABSI incidence during the pandemic and the likely impacts of hospital COVID-19 prevention activities on central-line insertion and maintenance practices have been previously documented.\textsuperscript{4,6,21} CAUTIs and VAEs were also reported more frequently in 2020 than 2019. A longer patient length-of-stay, additional comorbidities and higher patient acuity levels, and a longer duration of device use in 2020 could have contributed to an overall increased risk of a device-associated infection during the pandemic. In addition, some studies identified an increased risk of ventilator-associated conditions in critically ill COVID-19 patients.\textsuperscript{2,20} The characteristic worsening of respiratory status in some patients with COVID-19 resulted in an increase in the number of hospitalized patients in 2020 that required ventilation, and an increase in patients’ average duration of ventilation, both of which could have contributed to an increased risk of VAE. Almost all states previously identified by CDC with a high COVID-19 hospital admission burden observed increases in their 2020-Q2 CLABSI and VAE SIRs compared to 2019, most of which were statistically significant.\textsuperscript{1}

Preliminary data for 2020-Q4 showed a large increase of 34\% in the national MRSA bacteremia SIR compared to 2019-Q4. There were 2,715 MRSA bacteremia events reported for 2020-Q4, which is 41\% higher than the number of events reported by the same set of hospitals in 2019-Q4. Further investigation is needed to identify the source of these additional events. A previous study found that device-associated infections, particularly those related to central-lines, are a common source of MRSA bacteremia; thus, the increase in MRSA bacteremia in 2020 is possibly a result of inadequate central-line insertion and maintenance practices.\textsuperscript{4,6,21} However, preliminary NHSN data show no substantial changes in 2020, compared to 2019, in the proportion of CLABSI caused by \textit{S. aureus}, or in the proportion of \textit{S. aureus} CLABSIs that are resistant
to methicillin (data not shown). *S. aureus* has been identified as a common cause of secondary bacterial infection in COVID-19 patients.7,9 One meta-study found that >25% of all coinfections in COVID-19 patients were related to *S. aureus*, more than half of which were MRSA.23 Whether some of the MRSA bacteremia events reported to NHSN in 2020 occurred as secondary infections in patients with COVID-19 remains unknown.

The increased focus on hand hygiene, environmental cleaning, patient isolation, and use of PPE during 2020, combined with continued inpatient antimicrobial stewardship programs and a marked decline in outpatient antibiotic prescribing, may have resulted in decreases in the CDI SIRs during 2020 compared to 2019.5,23

This analysis has several limitations. The 2020-Q4 data were analyzed prior to the CMS HACRP reporting deadline of May 17, 2021, and therefore may be incomplete. This analysis was restricted to hospitals that reported data for both 2019 and 2020; new hospitals and units that opened in 2020 were not included. Thus, this paper does not reflect all HAIs that occurred in the United States. Information on the voluntarily reported COVID-19 status of patients with HAIs was not explored. In addition, we focused solely on ACHs for this analysis, and did not address HAI incidence in other settings that may have cared for COVID-19 patients, such as critical access and long-term ACHs.

This is the first comprehensive look at the impact of COVID-19 on HAI incidence at the national and state levels. Substantial increases in CLABSSIs, CAUTIs, VAEs, and MRSA bacteremia were observed. The year 2020 marked an unprecedented time for hospitals, many of which were faced with extraordinary circumstances of increased patient caseload, staffing challenges, and other operational changes that limited the implementation and effectiveness of standard infection prevention practices. A regular review of HAI surveillance data is critical for hospitals to identify gaps in prevention and address any observed increases in HAIs. Infection prevention staff should continue to reinforce infection prevention practices in their facilities, and consider the importance of building resiliency in their programs to withstand future public health emergencies.

**Supplementary material.** To view supplementary material for this article, please visit https://doi.org/10.1017/ice.2021.362

**Acknowledgments.** The authors express gratitude to all infection prevention staff in US healthcare facilities for their continued efforts in HAI surveillance and prevention, and for working tirelessly to keep all patients safe during an unprecedented public health emergency. We also thank the members of NHSN Protocol and Validation Team for their continued dedication to NHSN, patient safety, and for providing continued support to NHSN users in their HAI surveillance efforts during the COVID-19 pandemic: Katherine Allen-Bridson, Dominque Godfrey-Johnson, Cindy Gross, Denise Leaptop, Nigel Lewis, Bonnie Norrick, Melissa Otis, LaTasha Powell, Victoria Russo, Henrietta Smith, Jennifer Watkins. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention.

**Financial support.** No financial support was provided relevant to this article.

**Conflicts of interest.** All authors report no conflicts of interest relevant to this article.

**References**

1. Sapiano MRP, Dudeck MA, Soe M, et al. Impact of coronavirus disease 2019 (COVID-19) on US hospitals and patients, April–July 2020. *Infect Control Hosp Epidemiol* 2021. doi: 10.1017/ice.2021.69.

2. Rebmann T, Alvino RT, Holdsworth JE. Availability and crisis standards of care for personal protective equipment during fall 2020 of the COVID-19 pandemic: a national study by the APIC COVID-19 task force. *Am J Infect Control* 2021;49:657–662.

3. Weiner-Lastinger LM, Dudeck MA, Allen-Bridson K, et al. Changes in the number of intensive care unit bed units in US hospitals during the early months of the COVID-19 pandemic, as reported to the National Healthcare Safety Network’s COVID-19 module. *Infect Control Hosp Epidemiol* 2021. doi: 10.1017/ice.2021.266.

4. Fukih MG, Bufalino A, Sturm L, et al. Coronavirus disease 2019 (COVID-19) pandemic, central-line-associated bloodstream infection (CLABSI), and cather-associated urinary tract infection (CAUTI): the urgent need to refocus on hardwiring prevention efforts. *Infect Control Hosp Epidemiol* 2021. https://doi.org/10.1017/ice.2021.70.

5. McMullen KM, Smith BA, Rebmann T. Impact of SARS-CoV-2 on hospital acquired infection rates in the United States: predictions and early results. *Am J Infect Control* 2020;48:1409–1411.

6. LeRose J, Sandhu A, Polistico J, et al. The impact of COVID-19 response on central-line-associated bloodstream infections and blood culture contamination rates at a tertiary-care center in greater Detroit area. *Infect Control Hosp Epidemiol* 2020. doi: 10.1017/ice.2020.1335.

7. Kumar G, Adams A, Hererra M, et al. Predictors and outcomes of healthcare-associated infections in COVID-19 patients. *Int J Infect Dis* 2020;104:287–292.

8. Rips M, Galli L, Poli A, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. *Clin Microbiol Infect* 2021;27:451–457.

9. Smith L, Karaba SM, Amoah J, et al. Hospital-acquired infections among adult patients admitted for coronavirus disease 2019 (COVID-19). *Infect Control Hosp Epidemiol* 2021. doi: 10.1017/ice.2021.148.

10. Patel P, Weiner-Lastinger LM, Dudeck MA, et al. Impact of COVID-19 pandemic on central-line–associated bloodstream infections during the early months of 2020, National Healthcare Safety Network. *Infect Control Hosp Epidemiol* 2021. doi: 10.1017/ice.2021.108.

11. The NHSN standardized infection ratio (SIR): a guide to the SIR. Centers for Disease Control and Prevention website. https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/nhsn-sir-guide.pdf. Updated February 2021. Accessed May 11, 2021.

12. 2019 National and State Healthcare-Associated Infections Progress Report. Centers for Disease Control and Prevention (CDC) website. https://www.cdc.gov/hai/data/portal/progess-report.html. Published December 2020. Accessed April 30, 2021.

13. Data Archive: National and State HAI Progress Reports or SIR Reports. Centers for Disease Control and Prevention (CDC) website. https://www.cdc.gov/hai/data/archive/archive.html. Accessed April 30, 2021.

14. Nkwata A, Soe M, Li Q, Godfrey-Johnson D, Edwards J, Dudeck M. Incidence trends of central-line-associated bloodstream infections in acute-care hospitals, NHSN, 2009–2018. *Infect Control Hosp Epidemiol* 2020;41 suppl 1:S294–S295.

15. Jones K, Mu Y, Li Q, et al. National reporting trend for HO-MRSA bacteremia LabID events, 2010–2018. *Infect Control Hosp Epidemiol* 2020;41 suppl 1:S68–S69.

16. National Healthcare Safety Network patient safety component manual. Centers for Disease Control and Prevention website. https://www.cdc.gov/nhsn/pdfs/pscmanual/pscmanual_current.pdf. Updated January 2021. Accessed May 10, 2021.

17. FY 2021 IPPS final rule home page. Centers for Medicare and Medicaid Services website. https://www.cms.gov/medicare/acute-inpatient-pps/fy-2021-ips-final-rule-home-page. Updated January 2021. Accessed May 10, 2021.

18. CMS announces relief for clinicians, providers, hospitals and facilities participating in quality reporting programs in response to COVID-19. Centers for Medicare and Medicaid Services website. https://www.cms.gov/newsroom/press-releases/cms-announces-relief-clinicians-providers-hospitals-and-facilities-participating-quality-reporting. Published March 22, 2020. Accessed June 3, 2021.

19. The NHSN standardized utilization ratio (SUR): a guide to the SUR. Centers for Disease Control and Prevention website. https://www.cdc.gov/nhsn/
20. Maes M, Higginson E, Pereira-Dias J, et al. Ventilator-associated pneumonia in critically ill patients with COVID-19. Crit Care 2021;25:130.
21. Ham DC, See I, Novosad S, et al. Investigation of hospital-onset meticillin-resistant Staphylococcus aureus bloodstream infections at eight high-burden acute-care facilities in the USA, 2016. J Hosp Infect 2020;105:502–508.
22. Adeiza SS, Shuaibu AB, Shuaibu GM. Random effects meta-analysis of COVID-19/S. aureus partnership in coinfection. GMS Hyg Infect Control 2020. doi:10.3205/dgkh000364.
23. The intersection of antibiotic resistance (AR), antibiotic use (AU), and COVID-19. Department of Health and Human Services website. https://www.hhs.gov/sites/default/files/antibiotic-resistance-antibiotic-use-covid-19-paccarb.pdf. Published February 10, 2021. Accessed June 28, 2021.